Haleon Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Haleon kazanç ve gelirin sırasıyla yıllık 10.6% ve 3.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 13% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.6%

Kazanç büyüme oranı

13.0%

EPS büyüme oranı

Personal Products kazanç büyümesi	25.3%
Gelir büyüme oranı	3.6%
Gelecekteki özkaynak getirisi	9.5%
Analist kapsamı	Good
Son güncelleme	01 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NYSE:HLN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	11,998	1,813	1,883	N/A	13
12/31/2025	11,484	1,664	1,730	N/A	16
12/31/2024	11,224	1,487	1,451	N/A	15
9/30/2024	11,240	1,208	N/A	N/A	N/A
6/30/2024	11,258	1,088	2,455	2,193	N/A
3/31/2024	11,235	1,083	N/A	N/A	N/A
12/31/2023	11,302	1,049	2,010	2,100	N/A
9/30/2023	11,314	1,250	N/A	N/A	N/A
6/30/2023	11,408	1,230	1,796	2,132	N/A
3/31/2023	11,217	1,106	N/A	N/A	N/A
12/31/2022	10,858	1,060	1,771	2,063	N/A
9/30/2022	10,560	1,390	N/A	N/A	N/A
6/30/2022	10,158	1,416	1,604	1,802	N/A
3/31/2022	9,866	1,500	N/A	N/A	N/A
12/31/2021	9,545	1,390	1,195	1,356	N/A
12/31/2020	9,892	1,145	2,013	1,407	N/A
12/31/2019	8,480	655	663	786	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HLN 'nin tahmini kazanç büyümesi (yıllık 10.6% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: HLN şirketinin kazançlarının (yıllık 10.6% ) US pazarından (yıllık 15.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: HLN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: HLN şirketinin gelirinin (yıllık 3.6% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: HLN şirketinin gelirinin (yıllık 3.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: HLN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9.5 %).

Haleon Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Recent updates

Haleon: Tailwinds Are Mostly Priced In

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 455,701,825 shares, representing 4.99% of its issued share capital., under the authorization approved on May 8, 2024.

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Dr. Reddy'S Laboratories S.A. completed the acquisition of Northstar Switzerland SARL from Haleon plc (LSE:HLN).

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Haleon plc, Annual General Meeting, May 08, 2024

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

Haleon: A Hidden Gem In The Consumer Health Market

Haleon exploring sale of ChapStick Brand - report

Haleon plc Announces Board Changes

Haleon said to evaluate potential deals to increase its size - report

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon: Undervalued With Clear Catalyst Ahead

Former GSK consumer health unit Haleon hits all-time low

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin